December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

14.35 USD +1.44 (+11.15%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
3 Stocks That Could Realistically Triple Your Money in 2021
No kidding around ... here's how they truly can. 
Tags VXRT JUSHF Market News
From Motley Fool
2 Under-the-Radar COVID Vaccine Stocks to Buy for 2021
Transport and storage of their potential vaccines would be a piece of cake. 
Tags VXRT Market News MRNA
From Motley Fool
Could This Under-the-Radar COVID Stock Be a Millionaire-Maker?
This biotech just might have what it takes. 
Tags ALT Market News
From Motley Fool
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
3 Coronavirus Stocks Poised to Soar in 2021
They're risky but could deliver huge returns in the new year. 
Tags Market News VXRT NVAX
From Motley Fool
Why These Health Care Stocks Are Moving Today
Altimmune (NASDAQ: ALT) shares weretrading higher Wednesday after the company announced it began a multinational Phase 2 clinical ... 
Tags INCY ALT why it's moving
From Benzinga
Why Altimmune's Stock is Trading Higher Today
The Price And Volume Action In Altimmune's Stock Today Altimmune’s (NASDAQ: ALT) stock is trading up 4.36% to a price of ... 
Tags Movers BZ/WIIM Market News
From Benzinga
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
From GlobeNewswire News Releases
35 Stocks Moving in Wednesday's Pre-Market Session
Gainers Conifer Holdings, Inc. (NASDAQ: CNFR) shares rose 189.4% to $7.67 in pre-market trading after gaining around 8% on ... 
Tags Integrated Telecommunication Services CETX ATIF
From Benzinga
Now Could Be the Perfect Time to Buy This Under-the-Radar COVID Vaccine Stock
It's down, but not out. 
Tags MRNA ALT Market News
From Motley Fool
Sum Up The Parts: IBB Could Be Worth $181
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Iridex (NASDAQ:IRIX) stock increased by 24.48% to $3.0 during Monday's after-market session. Today's trading volume ... 
Tags ARCT Benzinga NMTR
From Benzinga
70 Biggest Movers From Thursday
Gainers Air T, Inc. (NASDAQ: AIRT) shares jumped 293.6% to close at $38.38 on Thursday after the company announced plans to form a ... 
Tags JAGX Benzinga STAF
From Benzinga
The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning ... 
Tags BLPH FDA SGTX
From Benzinga
ALT Crosses Below Key Moving Average Level
In trading on Thursday, shares of Altimmune Inc (ALT) crossed below their 200 day moving average of $11.83, changing hands as low as $11.25 per share. Altimmune Inc shares are currently trading off... 
Tags Stocks
From Market News Video
42 Stocks Moving In Thursday's Mid-Day Session
Gainers Air T, Inc. (NASDAQ: AIRT) gained 85.6% to $18.10 after the company announced plans to form a new aircraft equity vehicle. ... 
Tags Penny Stocks Top Gainers HCHC
From Benzinga
Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10% (ALT)
From Business Insider
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Avinger (NASDAQ:AVGR) shares moved upwards by 98.26% to $0.69 during Thursday's pre-market session. The ... 
Tags ONTX Market News Pre/Market Outlook
From Benzinga
36 Stocks Moving in Thursday's Pre-Market Session
Gainers Senseonics Holdings, Inc. (NYSE: SENS) shares rose 79.7% to $1.16 in pre-market trading after the company lifted its sales ... 
Tags BTWN TRIT STIC
From Benzinga
Altimmune Selloff On Clinical Hold A Buying Opportunity, Says JMP Securities
After speaking with management, JMP Securities analyst Jonathan Wolleben expects Altimmune to resolve the AdCOVID IND clinical hold in early January with Phase 1 data still expected in Q1. 
Tags Stocks / Equities
From Blogs - TalkMarkets
A Peek Into The Markets: US Stock Futures Up Ahead Of Christmas Break
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones recorded a gain of over 100 points in ... 
Tags Earnings SENS Small Cap
From Benzinga
5 Stocks To Watch For December 24, 2020
Some of the stocks that may grab investor focus today are: Senseonics Holdings Inc (NYSE: SENS) lifted its sales guidance for the ... 
Tags STAF Benzinga News
From Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Bellicum Pharmaceuticals (NASDAQ:BLCM) shares rose 9.91% to $4.1 during Wednesday's after-market session. Trading volume ... 
Tags ALT General JAGX
From Benzinga
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
From GlobeNewswire News Releases
Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks?
2021 may be their big year for growth and product news. 
Tags PFE MRNA ARCT
From Motley Fool
Why Altimmune Stock Is Soaring Today
Investors are excited about an analyst's bullish opinion about the biotech stock. 
Tags Market News ALT
From Motley Fool
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
From GlobeNewswire News Releases
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
Preclinical data suggest potential for ALT-801 to address a significant unmet medical need; Phase 1 data readout anticipated in Q2 2021 
From GlobeNewswire News Releases
Interesting ALT Put And Call Options For January 2021
Investors in Altimmune Inc (ALT) saw new options begin trading this week, for the January 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALT options chain... 
Tags Stocks
From Market News Video
62 Biggest Movers From Yesterday
Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 59.1% to close at $6.49 on Wednesday. Merrimack ... 
Tags FCEL Movers From Yesterday EARS
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.